Phenomix endocrine news

Phenomix said it has cut most of its 45 employees and is winding down operations after failing to find a new partner in North America to develop and commercialize diabetes candidate dutogliptin. In April, Forest Laboratories Inc. (NYSE:FRX, New York, N.Y.) ended a 2008 deal with Phenomix that granted Forest North American rights to the dipeptidyl peptidase-4 (DPP-4), which is in Phase III testing (see BioCentury, April 26). ...